Sarah John, Briana Heinly, Klaus Helm, Matthew Helm
{"title":"Persistent Diffuse Telangiectatic Eruption Associated With Loncastuximab Tesirine.","authors":"Sarah John, Briana Heinly, Klaus Helm, Matthew Helm","doi":"10.1097/DAD.0000000000003317","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>Loncastuximab tesirine (LT) is a CD19-directed antibody-drug conjugate approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma. We report a case of a persistent, diffuse telangiectatic eruption that developed shortly after initiation of LT. Histopathologic examination revealed mild epidermal thinning with superficial ectatic vessels, large conspicuous fibroblasts, solar elastosis, and scattered dermal melanophages. This case highlights a distinctive, minimally inflammatory, vascular-predominant reaction pattern associated with LT. This morphology has been only recently recognized as a potential adverse effect of antibody-drug conjugate medications, with very few published literature on the subject. Because the use of antibody-drug conjugates continues to expand, recognition of this pattern is important, particularly given its persistence even after therapy cessation and limited response to corticosteroid treatment.</p>","PeriodicalId":50967,"journal":{"name":"American Journal of Dermatopathology","volume":" ","pages":"675-677"},"PeriodicalIF":0.8000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Dermatopathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/DAD.0000000000003317","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/5/11 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Abstract: Loncastuximab tesirine (LT) is a CD19-directed antibody-drug conjugate approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma. We report a case of a persistent, diffuse telangiectatic eruption that developed shortly after initiation of LT. Histopathologic examination revealed mild epidermal thinning with superficial ectatic vessels, large conspicuous fibroblasts, solar elastosis, and scattered dermal melanophages. This case highlights a distinctive, minimally inflammatory, vascular-predominant reaction pattern associated with LT. This morphology has been only recently recognized as a potential adverse effect of antibody-drug conjugate medications, with very few published literature on the subject. Because the use of antibody-drug conjugates continues to expand, recognition of this pattern is important, particularly given its persistence even after therapy cessation and limited response to corticosteroid treatment.
期刊介绍：
The American Journal of Dermatopathology offers outstanding coverage of the latest diagnostic approaches and laboratory techniques, as well as insights into contemporary social, legal, and ethical concerns. Each issue features review articles on clinical, technical, and basic science advances and illuminating, detailed case reports.
With the The American Journal of Dermatopathology you''ll be able to:
-Incorporate step-by-step coverage of new or difficult-to-diagnose conditions from their earliest histopathologic signs to confirmatory immunohistochemical and molecular studies.
-Apply the latest basic science findings and clinical approaches to your work right away.
-Tap into the skills and expertise of your peers and colleagues the world over peer-reviewed original articles, "Extraordinary cases reports", coverage of practical guidelines, and graphic presentations.
-Expand your horizons through the Journal''s idea-generating forum for debating controversial issues and learning from preeminent researchers and clinicians
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
